Media coverage about Otonomy (NASDAQ:OTIC) has trended somewhat positive recently, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Otonomy earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.0840287412142 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the headlines that may have effected Accern’s scoring:
- Otonomy, Inc. (NASDAQ:OTIC) – An Eye on Data – Nasdaq Journal (press release) (nasdaqjournal.com)
- $250,000.00 in Sales Expected for Otonomy Inc (OTIC) This Quarter (americanbankingnews.com)
- Otonomy to Present at the J.P. Morgan Healthcare Conference (finance.yahoo.com)
- Otonomy Inc (OTIC) Given Consensus Rating of “Hold” by Brokerages (americanbankingnews.com)
A number of equities analysts have recently weighed in on the company. Zacks Investment Research downgraded Otonomy from a “buy” rating to a “hold” rating in a research note on Thursday. Piper Jaffray Companies restated a “hold” rating and issued a $8.00 target price on shares of Otonomy in a research note on Friday, November 10th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $9.15.
Otonomy (NASDAQ:OTIC) last announced its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.15. Otonomy had a negative return on equity of 60.74% and a negative net margin of 7,899.03%. The firm had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.43 million. The business’s revenue was down 12.8% compared to the same quarter last year. research analysts anticipate that Otonomy will post -2.88 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Otonomy (OTIC) Share Price” was first posted by Week Herald and is owned by of Week Herald. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://weekherald.com/2018/01/08/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-otonomy-otic-share-price.html.
Otonomy Company Profile
Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase.
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.